Insulet | PODD - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Abbott USD 10.46B 1.15B 2026-06
Align Technology USD 864.87M 2.84M 2026-06
AtriCure USD 143.94M 3.22M 2026-06
Baxter International USD 2.68B 3.36B 2026-06
Becton, Dickinson and Co. USD 24.42B 283M 2026-06
Boston Scientific USD 4.2B 49M 2026-06
Cardinal Health USD 62.86B 65.69B 2026-06
Cooper Companies USD 844.2M 268.3M 2026-06
Dexcom USD 990.1M 53.5M 2026-06
Edwards Lifesciences USD 1.22B 87.6M 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Globus Medical USD 835.58M 239.73M 2026-06
ICU Medical USD 491.25M 8.59M 2026-06
Inogen USD 49.14M 665K 2024-09
Insulet USD 672M 32.3M 2026-06
Integra LifeSciences USD 1.04B 971K 2026-06
J&J USD 17.83B 388M 2026-06
Medtronic USD 7.92B 203M 2026-06
Merit Medical Systems USD 358.44M 20.72M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Solventum Corp USD 4.8B 169M 2026-06
Stryker USD 4.8B 118M 2026-06
Tandem Diabetes Care USD 268.35M 3.7M 2026-06
Teleflex USD 2.9B 179.9M 2026-06
West Pharmaceutical Services USD 2.99B 200K 2026-06
Zimmer Biomet Holdings USD 1.83B 140.7M 2026-06